{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:12:06Z","timestamp":1792725126290,"version":"4.5.0"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T00:00:00Z","timestamp":1657929600000},"content-version":"am","delay-in-days":318,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.ejca.2021.06.026","type":"journal-article","created":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T23:42:59Z","timestamp":1626478979000},"page":"175-189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["The role of tyrosine kinase inhibitors in the treatment of HER2+ metastatic breast cancer"],"prefix":"10.1016","volume":"154","author":[{"given":"Fanny","family":"Le Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Di\u00e9ras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1781-2518","authenticated-orcid":false,"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2021.06.026_bib1","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/nrc3559","article-title":"Targeting the ERBB family in cancer: couples therapy","volume":"13","author":"Tebbutt","year":"2013","journal-title":"Nat Rev Canc"},{"key":"10.1016\/j.ejca.2021.06.026_bib2","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1016\/S0140-6736(16)32417-5","article-title":"HER2-positive breast cancer","volume":"389","author":"Loibl","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2021.06.026_bib3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.ejca.2021.06.026_bib4","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.06.026_bib5","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1200\/JOP.18.00290","article-title":"Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO clinical practice guideline update summary","volume":"14","author":"Giordano","year":"2018","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.ejca.2021.06.026_bib6","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.06.026_bib7","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.06.026_bib8","doi-asserted-by":"crossref","first-page":"6404","DOI":"10.1158\/1078-0432.CCR-13-0790","article-title":"CNS metastases in breast cancer: old challenge, new frontiers","volume":"19","author":"Lin","year":"2013","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.ejca.2021.06.026_bib9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.clbc.2017.07.017","article-title":"Changing natural history of HER2-positive breast cancer metastatic to the brain in the era of new targeted therapies","volume":"18","author":"Mounsey","year":"2018","journal-title":"Clin Breast Canc"},{"key":"10.1016\/j.ejca.2021.06.026_bib10","first-page":"85","article-title":"The effects of the novel, reversible epidermal growth factor receptor\/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in\u00a0vitro and in\u00a0vivo","volume":"1","author":"Rusnak","year":"2001","journal-title":"Mol Canc Therapeut"},{"key":"10.1016\/j.ejca.2021.06.026_bib11","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1158\/1078-0432.CCR-09-1112","article-title":"Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in\u00a0vitro and in\u00a0vivo","volume":"16","author":"Wainberg","year":"2010","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.ejca.2021.06.026_bib12","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1158\/0008-5472.CAN-03-2868","article-title":"Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase","volume":"64","author":"Rabindran","year":"2004","journal-title":"Canc Res"},{"key":"10.1016\/j.ejca.2021.06.026_bib13","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1158\/1535-7163.MCT-19-0873","article-title":"Preclinical activity of HER2-selective tyrosine kinase inhibitor tucatinib as a single agent or in combination with trastuzumab or docetaxel in solid tumor models","volume":"19","author":"Kulukian","year":"2020","journal-title":"Mol Canc Therapeut"},{"key":"10.1016\/j.ejca.2021.06.026_bib14","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejps.2017.01.021","article-title":"Discovery and development of pyrotinib: a novel irreversible EGFR\/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer","volume":"110","author":"Li","year":"2017","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.ejca.2021.06.026_bib15","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1124\/jpet.112.197756","article-title":"Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker","volume":"343","author":"Solca","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ejca.2021.06.026_bib16","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.06.026_bib17","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1634\/theoncologist.2009-0181","article-title":"Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial","volume":"15","author":"Cameron","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2021.06.026_bib18","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1200\/JCO.2011.35.6725","article-title":"Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 study","volume":"30","author":"Blackwell","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.06.026_bib19","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1200\/JCO.2014.56.9590","article-title":"Lapatinib or trastuzumab plus taxane therapy for human epidermal growth factor receptor 2-positive advanced breast cancer: final results of NCIC CTG MA.31","volume":"33","author":"Gelmon","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.06.026_bib20","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2014.57.1794","article-title":"CEREBEL (EGF111438): a phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer","volume":"33","author":"Pivot","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.06.026_bib21","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S1470-2045(17)30312-1","article-title":"Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial","volume":"18","author":"Dieras","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.06.026_bib22","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.1200\/JCO.2009.23.3734","article-title":"Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer","volume":"27","author":"Johnston","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.06.026_bib23","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1200\/JCO.2017.74.7824","volume":"36","author":"Johnston","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.06.026_bib24","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1093\/annonc\/mdm601","article-title":"A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer","volume":"19","author":"Burstein","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.06.026_bib25","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1200\/JCO.2008.21.4437","article-title":"Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer","volume":"28","author":"Blackwell","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.06.026_bib26","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1200\/JCO.19.00108","article-title":"Pyrotinib or lapatinib combined with capecitabine in HER2-positive metastatic breast cancer with prior taxanes, anthracyclines, and\/or trastuzumab: a randomized, phase II study","volume":"37","author":"Ma","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.06.026_bib27","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1016\/j.ejca.2013.07.142","article-title":"A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer","volume":"49","author":"Martin","year":"2013","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2021.06.026_bib28","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1200\/JCO.20.00147","article-title":"Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with \u22652 HER2-directed regimens: phase III NALA trial","volume":"38","author":"Saura","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.06.026_bib29","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S1470-2045(15)00551-3","article-title":"Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"Chan","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.06.026_bib30","article-title":"Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase III ExteNET trial","volume":"21","author":"Chan","year":"2021","journal-title":"Clin Breast Canc"},{"key":"10.1016\/j.ejca.2021.06.026_bib31","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jamaoncol.2016.0237","article-title":"Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer: the NEfERT-T randomized clinical trial","volume":"2","author":"Awada","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2021.06.026_bib32","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.06.026_bib33","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1158\/1078-0432.CCR-16-1496","article-title":"Phase I study of ONT-380, a HER2 inhibitor, in patients with HER2(+)-advanced solid tumors, with an expansion cohort in HER2(+) metastatic breast cancer (MBC)","volume":"23","author":"Moulder","year":"2017","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.ejca.2021.06.026_bib34","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1001\/jamaoncol.2018.1812","article-title":"Tucatinib combined with ado-trastuzumab emtansine in advanced ERBB2\/HER2-positive metastatic breast cancer: a phase 1b clinical trial","volume":"4","author":"Borges","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2021.06.026_bib35","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1200\/JCO.2016.69.6179","article-title":"Phase I study and biomarker analysis of pyrotinib, a novel irreversible pan-ErbB receptor tyrosine kinase inhibitor, in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer","volume":"35","author":"Ma","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.06.026_bib36","series-title":"A study of pyrotinib in combination with trastuzumab and docetaxel in patients with HER2 metastatic breast cancer","author":"ClinicalTrialsgov","year":"2020"},{"key":"10.1016\/j.ejca.2021.06.026_bib37","series-title":"A study of pyrotinib plus capecitabine in patients with HER2+ metastatic breast cancer","author":"ClinicalTrialsgov","year":"2020"},{"key":"10.1016\/j.ejca.2021.06.026_bib38","series-title":"Pyrotinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2+ metastatic breast cancer (PHOEBE)","author":"ClinicalTrialsgov","year":"2020"},{"key":"10.1016\/j.ejca.2021.06.026_bib39","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1470-2045(15)00540-9","article-title":"Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial","volume":"17","author":"Harbeck","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.06.026_bib40","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S1470-2045(13)70017-2","article-title":"CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)","volume":"14","author":"Pestalozzi","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.06.026_bib41","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.06.026_bib42","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1470-2045(12)70432-1","article-title":"Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study","volume":"14","author":"Bachelot","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.06.026_bib43","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/annonc\/mdu486","article-title":"Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast\u00a0cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA","volume":"26","author":"Krop","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.06.026_bib44","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ejca.2017.07.024","article-title":"The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: a systematic review and pooled analysis","volume":"84","author":"Petrelli","year":"2017","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2021.06.026_bib45","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.2015.63.0343","article-title":"Translational breast cancer research consortium (TBCRC) 022: a phase II trial of neratinib for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases","volume":"34","author":"Freedman","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.06.026_bib46","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1200\/JCO.18.01511","article-title":"TBCRC 022: a phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases","volume":"37","author":"Freedman","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.06.026_bib47","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1200\/JCO.20.00775","article-title":"Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2+ breast cancer with brain metastases in the HER2CLIMB trial","volume":"38","author":"Lin","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.06.026_bib48","series-title":"European society of medical oncology; 2020; Virtual Congress","article-title":"Impact of tucatinib on progression-free survival in patients with HER2+ metastatic breast cancer and stable or active brain metastases","author":"Bachelot","year":"2020"},{"key":"10.1016\/j.ejca.2021.06.026_bib49","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S1470-2045(15)00373-3","volume":"16","author":"Cort\u00e9s","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.06.026_bib50","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3747\/co.21.2241","article-title":"Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors","volume":"21","author":"Hirsh","year":"2014","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ejca.2021.06.026_bib51","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10549-018-05102-x","article-title":"The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea","volume":"175","author":"Rugo","year":"2019","journal-title":"Breast Canc Res Treat"},{"key":"10.1016\/j.ejca.2021.06.026_bib52","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10549-007-9860-9","article-title":"Pooled analysis of diarrhea events in patients with cancer treated with lapatinib","volume":"112","author":"Crown","year":"2008","journal-title":"Breast Canc Res Treat"},{"key":"10.1016\/j.ejca.2021.06.026_bib53","series-title":"SABCS; 2020; Virtual Congress","article-title":"Bringing diarrhea under CONTROL: dose escalation reduces neratinib-associated diarrhea and improves tolerability in HER2-positive early-stage breast cancer","author":"Ruiz-Borrego","year":"2020"},{"key":"10.1016\/j.ejca.2021.06.026_bib54","series-title":"Nerlynx (neratinib) US prescribing information","author":"Puma Biotechnology Inc","year":"2020"},{"key":"10.1016\/j.ejca.2021.06.026_bib55","series-title":"ASCO","article-title":"Management of adverse events in patients with HER2+ metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine (HER2CLIMB)","author":"Okines","year":"2020"},{"key":"10.1016\/j.ejca.2021.06.026_bib56","series-title":"Tukysa (tucatinib) US prescribing information","author":"Seagen Inc","year":"2020"},{"key":"10.1016\/j.ejca.2021.06.026_bib57","series-title":"Tukysa (tucatinib) European summary of product characteristics","author":"Seagen Inc","year":"2021"},{"key":"10.1016\/j.ejca.2021.06.026_bib58","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s10549-008-0020-7","article-title":"Analysis of dermatologic events in patients with cancer treated with lapatinib","volume":"114","author":"Lacouture","year":"2009","journal-title":"Breast Canc Res Treat"},{"key":"10.1016\/j.ejca.2021.06.026_bib59","article-title":"Mechanisms underlying skin disorders induced by EGFR inhibitors","volume":"2","author":"Holcmann","year":"2015","journal-title":"Mol Cell Oncol"},{"key":"10.1016\/j.ejca.2021.06.026_bib60","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1634\/theoncologist.12-7-756","article-title":"Lapatinib-associated toxicity and practical management recommendations","volume":"12","author":"Moy","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2021.06.026_bib61","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1159\/000508736","article-title":"AGO recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer: update 2020","volume":"15","author":"Ditsch","year":"2020","journal-title":"Breast Care"},{"key":"10.1016\/j.ejca.2021.06.026_bib62","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1200\/JCO.2014.56.3809","article-title":"Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2\u2013positive breast cancer","volume":"32","author":"Saura","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.06.026_bib63","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S1470-2045(18)30256-0","article-title":"Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study","volume":"19","author":"Murthy","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.06.026_bib64","first-page":"1795","article-title":"Abstract #1795: in\u00a0vitro and in\u00a0vivo activity of ARRY-380: a potent, small molecule inhibitor of ErbB2","volume":"69","author":"Pheneger","year":"2009","journal-title":"Canc Res"},{"key":"10.1016\/j.ejca.2021.06.026_bib65","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/bjc.2017.436","article-title":"Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and\/or HER2","volume":"118","author":"Bahleda","year":"2018","journal-title":"Br J Canc"},{"key":"10.1016\/j.ejca.2021.06.026_bib66","series-title":"Tykerb (lapatinib) European summary of product characteristics","author":"Novartis Pharmaceutical Corporation","year":"2020"},{"key":"10.1016\/j.ejca.2021.06.026_bib67","series-title":"Tykerb (lapatinib) US prescribing information","author":"Novartis Pharmaceutical Corporation","year":"2018"}],"updated-by":[{"DOI":"10.1016\/j.ejca.2021.09.020","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000}}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921004019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921004019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T01:06:32Z","timestamp":1678669592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921004019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":67,"alternative-id":["S0959804921004019"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.06.026","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.ejca.2021.09.020","asserted-by":"object"}]},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of tyrosine kinase inhibitors in the treatment of HER2+ metastatic breast cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.06.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}